Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Quality system
    • Investors
  • News & Media
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq

Category: 2016

2016

QUEST I FIM study completed

Posted on 25. September 20167. February 2018

Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.

2016

Qvanteq obtained government funding in the form of a new CTI/KTI project (19305.1 PFLS-LS)

Posted on 30. July 20167. February 2018

The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.  

Recent News

  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity
  • Qvanteq has moved to new offices

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG